The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49.
BP PLC
BP · NYSE (ADR) · Market cap $111.8B · 93,700 employees
BP p.l.c., an integrated energy company, engages in the oil and gas business worldwide.
Not yet scoredScreen close, 2026-09-21 · not a live quote
Screened 2026-09-21 · the tape above runs as of 09:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 43.16 against the desk's fair-value range, base estimate 42.14, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its distribution label.
BP PLC holds its Distribution at $43.16. The statistical read favours the buyers, held for 11 days.
| Phase | Distribution · caution |
| Quantitative state | The statistical read favours the buyers, held for 11 days |
| Price at the screen | $43.16 |
| Valuation | 35.52 trailing · 10.71 forward price to earnings |
| Values screen | Not scored · score 50.0 |
| Beta | -0.22 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Revenue purity | 0.00% | Below 5% | Only 0.0% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience OverlayThe quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on Don’t Buy Into Occupation / Palestinian BDS National Committee — category: Corporate Complicity Report / Annex 2 Company List. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
The Fair Value Range
Our framework reads FAIR VALUE: it trades above our $42.14 fair value estimate, weak competitive moat, 11.60% revenue growth.
Fair value range in , drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 2.4% above the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a weak moat. At the screened price it sits 2% above our $42.14 fair value: priced for the quality, not a bargain.
| Forward P/E | 10.7xfairly priced for its growth rate |
| Trailing P/E | 35.5xexpensive: the price assumes strong growth ahead |
| EPS, forward | 4.11 |
| Revenue growth | +11.6%steady growth |
| Profit margin | 1.7%barely profitable |
| Return on equity | 5.8%a modest return on shareholder capital |
| Dividend yield | 4.53% |
| Debt to equity | 0.96moderate, manageable leverage |
| Current ratio | 1.22adequate liquidity, worth monitoring |
| Beta | -0.22barely tracks the market's swings |
| Short interest, float | 0.01% |
| 52-week range | 28.41 - 48.27 |
| Moat | WEAK |
| Market cap | $111.8B |
| Employees | 93,700 |
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeBP trades on NYSE (ADR) (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 51%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (17 analysts) rates it buy, with a mean price target of $49.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-23 | Sosso (Mike) | 14,308 | $618,677 | ||
| 2026-03-18 | Lin (William-a) | 10,000 | $441,600 | ||
| 2026-01-02 | Norges Bank | 10,037,626 | · | ||
| 2025-08-06 | Hager (David) | 7,500 | $258,750 | ||
| 2025-04-11 | Norges Bank | 1,932,676 | · | ||
| 2024-12-20 | Meyer (Melody B.) | 3,000 | $85,740 | ||
| 2024-12-18 | Pai (Satish) | 1,500 | $43,935 | ||
| 2024-12-18 | Richardson (Karen) | 1,000 | $29,250 | ||
| 2024-11-14 | Pai (Satish) | 2,000 | $57,780 | ||
| 2024-09-23 | Norges Bank | · | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-06-15 | David Taylor | Republican | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $43.72 | -1.0% | $0.50 | $1,001 | +0.1% |
| 2 months | $45.91 | -5.8% | $0.50 | $953 | -4.7% |
| 3 months | $41.68 | +3.8% | $0.50 | $1,050 | +5.0% |
| 6 months | $34.68 | +24.8% | $1.00 | $1,277 | +27.7% |
| 1 year | $28.68 | +50.9% | $2.00 | $1,578 | +57.8% |
| 2 years | $32.08 | +34.9% | $3.92 | $1,471 | +47.1% |
| 3 years | $30.19 | +43.3% | $5.66 | $1,621 | +62.1% |
| 5 years | $21.46 | +101.7% | $8.49 | $2,413 | +141.3% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever BP does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.